Oncology Biomarkers 57.


Hausladen DA, et al., Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guérin and mitomycin C on urinary survivin levels and outcome, J Urol, 2003;170:230–34.


58. 59. 60. 61. 62.


Duffy MJ, et al., Survivin: a promising tumour biomarker, Cancer Lett, 2007;249:49–6.


Davies B, et al., Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer, J Urol, 2005;174:1767–70.


Klein A, et al., Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma, Cancer, 1998;82:349.


Guo B, et al., Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by realtime PCR, Exp Oncol, 2009;31:43–7.


Attallah AM, et al., Rapid diagnosis and follow up of bladder cancer patients using urinary high molecular weight cytokeratins, World J Urol, 2006;24: 345–52.


63. 64. 65. 66. 67. 68. 69. 70.


Ramos D, et al., Cytokeratin expression patterns in low- grade papillary urothelial neoplasms of the urinary bladder, Cancer, 2003;97:1876–83.


Mizutani Y, et al., Prognostic significance of soluble Fas in the serum of patients with bladder cancer, J Urol, 1998;160: 571–6.


Svatek RS, et al., Soluble Fas–A promising novel urinary marker for the detection of recurrent superficial bladder cancer, Cancer, 2006;106:1701–7.


Burton PB, et al., Caspase 3 and p27 as predictors of invasive bladder cancer, N Engl J Med, 2000;343:1418–20.


Kong G, et al., Bcl-2 and p53 expressions in invasive bladder cancers, Acta Oncol, 1998;37:715–20.


Righi S, et al., Does p53 immunostaining improve diagnostic accuracy in urine cytology?, Diagn Cytopathol, 1997;17:436.


Vet JA, et al., Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer, Clin Cancer Res, 1996;2:1055.


Salinas-Sánchez AS, et al., Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study, Urol Oncol, 2008;26: 620–26.


71.


Miyake M, et al., Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumour recurrence in non-muscle invasive bladder cancer, Cancer Sci, 2010;101(1):250–58.


72. 73.


Messing EM, Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma, Cancer Res, 1990;50:2530.


Lipponen P, Eskelinen M, Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors oncoprotein (c-erbB-2, p53) expression and long-term prognosis, Br J Cancer, 1994;69:1120.


74.


Kramer C, et al., Heparin-binding epidermal growth factor- like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome, Cancer, 2007;109:2016–24.


75. 76. 77. 78. 79. 80. 81.


Politi EN, et al., Epidermal growth factor receptor and proliferating cell nuclear antigen expression in urine ThinPrep specimens, Cytopathology, 2005;16:3030–38.


Miyake H, et al., Overexpression of CD44V8-10 in urinary exfoliated cells as an independent prognostic predictor in patients with urothelial cancer, J Urol, 2002;167(3):1282–7


Konety BR, et al., Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer, J Urol, 2000;164:634–9.


Konety BR, et al., Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4, Clin Cancer Res, 2000;6:2618–25.


Attallah AM, et al., An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer, BJU Int, 2005;96:334–9.


Bringuier PP, et al., Decreased E-Cadherin Immunoreactivity Correlates with Poor Survival in Patients with Bladder Tumours, Cancer Research, 1993;53:3241–5.


Margulis V, et al., Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease, Clin Cancer Res, 2006;12:7369–73.


82. 42 Margulis V, et al., Multi-institutional validation of the 94. 95. 91. 92. 93. 84.


predictive value of Ki-67 labeling index in patients with urinary bladder cancer, J Natl Cancer Inst, 2009;101:114–19.


83.


Sawczuk IS, et al., DD23 Biomarker. A prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC, Urol Oncol, 2002;7: 185–90.


Gilbert SM, et al., Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer, Urology, 2003;61:539–43.


85. 86. 87. 88. 89. 90.


Ablin RJ, et al., Tissue- and speciesspecific antigens of normal human prostatic tissue, J Immunol, 1970;104: 1329–39.


Stamey TA, et al., Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate, N Engl J Med, 1987;317:909–16.


Catalona WJ, et al., Measurement of prostate-specific antigen in serum as a screening test for prostate cancer, N Engl J Med, 1991;324:1156–61.


Bunting PS, Screening for prostate cancer with prostate- specific antigen: beware the biases, Clin Chim Acta, 2002;315:71–97.


Marberger M, et al., The clinical implications of the prostate cancer prevention trial, BJU Int, 2003;92:667–71.


Catalona WJ, et al., Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men, J Urol, 1994;151:1283–90.


Thompson IM, et al., Prevalence of prostate cancer among men with a prostatespecific antigen level N Engl J Med, 2004;350:2239–46.


Schröder FH, et al., Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 2009;360:1320–28.


Roobol MJ, et al., Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC), Eur Urol, 2009;56(4):584–91.


Andriole GL, et al., Mortality results from a randomized prostate-cancer screening trial, N Engl J Med, 2009;360: 1310–19.


Stenman UH, et al., A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer, Cancer Res, 1991;51:222–6.


96.


Catalona WJ, et al., Use of the percentage of free prostate- specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial, JAMA, 1998;279:1542–7.


97. 98.


Finne P, et al., Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of Eur Urol, 2008;54:362–70.


Nurmikko P, et al., Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146, Clin Chem, 2001;47:1415–23.


99.


Mikolajczyk SD, et al., Proenzyme forms of prostate- specific antigen in serum improve the detection of prostate cancer, Clin Chem, 2004;50:1017–25.


100. Linton HJ, et al., Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease, Clin Chem, 2003;49:253–9.


101. Mikolajczyk SD, et al., A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer, Cancer Res, 2001;61:6958–63.


102. Catalona WJ, et al., Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4ng/ml, J Urol, 2003;170:2181–5.


103. Lein M, et al., A multicenter clinical trial on the use of (-5, -7) pro-prostate specific antigen, J Urol, 2005;174: 2150–53.


104. Allard WJ, et al., Novel immunoassay for the measurement of complexed prostate-specific antigen in serum, Clin Chem, 1998;44:1216–23.


105. Partin AW, et al., Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial, J Urol, 2003;170:


1787–91.


106. Darson MF, et al., Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases, Urology, 1998;53:939–44.


107. Recker F, et al., The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma, Cancer, 1998;83:2540–47.


108. Scorilas A, et al., Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and percentage free PSA, Prostate, 2003;54:220–29.


109. Haese A, et al., Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies, J Urol, 2003;170:2269–73.


110. Raaijmakers R, et al., hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4–10ng/ml, Eur Urol, 2007;52:1358–64.


111. Steuber T, et al., Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum, Int J Cancer, 2006;118: 1234–40.


112. de la Taille A, Progensa TM PCA3 test for prostate cancer detection, Expert Rev Mol Diagn, 2007;7:491–7.


113. Deras IL, et al., PCA3: a molecular urine assay for predicting prostate biopsy outcome, J Urol, 2008;179: 1587–92.


114. Haese A, et al., Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy, Eur Urol, 2008;54:1081–8.


115. Marks LS, et al., PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy, Urology, 2007;69: 532–5.


116. Schilling D, et al., The Prostate Cancer gene 3 assay: indications for use in clinical practice, BJU Int, 2010;105(4): 452–5.


117. Nakanishi H, et al., PCA3 molecular urine assay correlates with prostate cancer tumour volume: implication in selecting candidates for active surveillance, J Urol, 2008;179:1804–9.


118. Dhir R, et al., Early identification of individuals with prostate cancer in negative biopsies, J Urol, 2004;171:1419–23.


119. Leman ES, et al., EPCA-2: a highly specific serummarker for prostate cancer, Urology, 2007;69:714–20.


120. Leman ES, et al., Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2, Prostate, 2009;69(11):1188–94.


121. Shariat SF, et al., Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis, J Clin Oncol, 2007;25:349–55.


122. Steuber T, et al., Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy, Int J Cancer, 2007;120:1499–1504.


123. Milanese G, et al., Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer, J Urol, 2009;181(3): 1393–1400.


124. Gupta A, et al., Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients, Eur Urol, 2009;55(5): 1124–33.


125. Fracalanza S, et al., Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination, Urol Int, 2005;75:57–61.


126. Taplin ME, et al., Prognostic significance of plasma chromogranin A levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study, Urology, 2005;66:386–91.


127. Marszalek M, et al., Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels


EUROPEAN UROLOGICAL REVIEW


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84